Omalizumab (Xolair®) increased the time to first exacerbation in patients with moderate-to-severe asthma compared with placebo

被引：0
|
作者：
O'Brien, JA
Fox, H
Thirlwell, J
机构：
[1] City Pk Med Ctr, Cape Town, South Africa
[2] Novartis Res Ctr, Horsham, W Sussex, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2001年 / 107卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
358
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [31] OMALIZUMAB IMPROVES QUALITY OF LIFE AND ASTHMA CONTROL IN CHINESE PATIENTS WITH MODERATE-TO-SEVERE ASTHMA: A RANDOMIZED PHASE III STUDY
    Li, J.
    Kang, J.
    Canvin, J.
    Wang, C.
    Zhong Nanshan
    Yang, J.
    Humphries, M.
    RESPIROLOGY, 2014, 19 : 2 - 2
  • [32] Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma
    Grossman, H. L.
    Schlender, Amory
    Alperin, Peter
    Stanley, Elizabeth L.
    Zhang, Jie
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (12) : 2779 - 2793
  • [33] Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma
    Corren, Jonathan
    Katelaris, Constance H.
    Castro, Mario
    Maspero, Jorge F.
    Ford, Linda B.
    Halpin, David M. G.
    Rice, Megan S.
    Radwan, Amr
    Deniz, Yamo
    Rowe, Paul J.
    Teper, Ariel
    Djandji, Michel
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58 (04)
  • [34] Cost-Effectiveness of Omalizumab in Moderate-to-Severe Asthma from the US Payer Perspective
    Campbell, J. D.
    Spackman, D. E.
    Swensen, A.
    Sullivan, S. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [35] Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma
    Busse, William W.
    Humbert, Marc
    Haselkorn, Tmirah
    Ortiz, Benjamin
    Trzaskoma, Benjamin L.
    Stephenson, Patricia
    Conde, Lorena Garcia
    Kianifard, Farid
    Holgate, Stephen T.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 124 (02) : 190 - 196
  • [36] Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma
    Oba, Y
    Salzman, GA
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (02) : 265 - 269
  • [37] Impact Of Body Mass Index On Omalizumab Response In Adults With Moderate-to-Severe Allergic Asthma
    Geng, Bob
    Dixon, Anne
    Yoo, Bongin
    Janampally, Pranathi
    Lyon, Robert
    Haselkorn, Tmirah
    Holweg, Cecile
    Jarjour, Nizar
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB18 - AB18
  • [38] Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma
    Geng, Bob
    Dixon, Anne E.
    Ko, Jinnie
    Janampally, Pranathi
    Haselkorn, Tmirah
    Holweg, Cecile T. J.
    Casale, Thomas B.
    Jarjour, Nizar
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 128 (05) : 553 - 560
  • [39] Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis
    Chong, Weikun
    Li, Hailang
    Wang, Juan
    FRONTIERS IN ALLERGY, 2023, 4
  • [40] Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review
    Corren, Jonathan
    Kavati, Abhishek
    Ortiz, Benjamin
    Colby, Jennifer A.
    Ruiz, Kimberly
    Maiese, Brett A.
    Cadarette, Sarah M., Jr.
    Panettieri, Reynold A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2017, 38 (04) : 250 - 263
12345